Giessen, Germany

Ann-Kristin Kollas

USPTO Granted Patents = 2 

Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2008-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ann-Kristin Kollas: Pioneering Innovations in Immunotherapy

Introduction

Ann-Kristin Kollas is a talented inventor based in Giessen, Germany. With a focus on advancing immunotherapy, she holds two significant patents that contribute to the field, particularly in the activation of gamma/delta T cells. Her work promises to revolutionize treatment protocols for various diseases in both humans and animals.

Latest Patents

Kollas's latest patents pertain to organophosphorus compounds designed for the activation of gamma/delta T cells. The present invention outlines these compounds of general formula (I), detailing their preparation and applications in the activation of gamma/delta T cells. Furthermore, her inventions are significant in screening GcpE and LytB enzyme inhibitors and offer promising prospects for prophylaxis and treatment of diseases.

Career Highlights

Ann-Kristin Kollas works at Bioagency AG, where her expertise and innovative approach significantly enhance the company’s research capabilities. Through her dedication and ingenuity, she contributes to the ongoing evolution of immunotherapeutic strategies, marking her as a prominent figure in her field.

Collaborations

Throughout her career, Kollas has collaborated with notable professionals, including colleagues Hassan Jomaa and Oliver Wolf. Together, they foster an environment of innovation and teamwork, driving forward the company's mission to create impactful research outcomes.

Conclusion

Ann-Kristin Kollas stands out as a remarkable inventor whose contributions are paving the way for advancements in immunotherapy. Her patents not only reflect her innovative spirit but also her commitment to improving health outcomes for humans and animals alike. As she continues to work with Bioagency AG and her team, the future looks bright for her ongoing research and the potential it holds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…